Aiolos Bio is a biotech company developing innovative therapies for respiratory diseases and immune conditions.
Aiolos Bio has raised $245.0M in total funding. The most recent round was Series A. The last funding was announced in October 2023.
Aiolos Bio's investors include RA Capital Management, Bain Capital Life Sciences, Sofinnova Investments, Forbion Capital Partners, Atlas Venture.
Aiolos Bio is headquartered in San Francisco, United States.
Aiolos Bio is a biotech company developing innovative therapies for respiratory diseases and immune conditions.
Aiolos Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aiolos Bio — Funding & Investors." VCBacked, October 24, 2023, https://www.vcbacked.co/company/aiolos-bio. Accessed September 29, 2026.
VCBacked. (2023). Aiolos Bio — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/aiolos-bio
{{cite web |title=Aiolos Bio — Funding & Investors |url=https://www.vcbacked.co/company/aiolos-bio |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated